Brief: Adial Pharmaceuticals Announces Positive Pre-Clinical Data For PNV2 As Drug Candidate For Triple Negative Breast Cancer
29/11/2021 14:11
Nov 29 (Reuters) - Adial Pharmaceuticals Inc ADIL.O :
* ADIAL PHARMACEUTICALS ANNOUNCES POSITIVE PRE-CLINICAL DATA
FOR
PNV2 AS A DRUG CANDIDATE FOR TRIPLE NEGATIVE BREAST CANCER
* ADIAL PHARMACEUTICALS INC - PLAN TO CONDUCT ADDITIONAL
PRE-CLINICAL RESEARCH WITH A GOAL OF ADVANCING PNV2 INTO
CLINICAL TRIALS IN 2022
Source text for Eikon: ID:nGNX2j4fkY
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)